Full Press Release Details
Corporate Presentation September 12, 2006
Confidential September 12, 2006 1
This presentation contains statements about Curis future expectations, plans and prospects that constitute
forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various
important factors, including risks relating to: both our and our collaborators ability to successfully research, obtain regulatory approvals for, develop and commercialize products based upon our technologies; our ability to obtain and
maintain proprietary protection for our technologies and product candidates; competitive pressures; our ability to maintain strategic collaborations, including with Genentech, Ortho Biotech and Wyeth; our ability to succeessfully execute on, and
achieve favorable results from, our chemistry efforts in China; our ability to raise additional funds to finance our operations; and those factors described in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2006, and other
reports that we file with SEC.
The forward-looking statements included in this presentation represent our views as of the
date of this presentation. We anticipate that subsequent events and developments will cause our views to change. While we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so. These
forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this presentation.
A Balanced Business Model
A Portfolio Approach to Drug Development
Partnerships with top-tier Pharma
expected to provide validation, access to world leading drug development competencies, higher probabilities of success and reduce reliance upon capital markets
Potential cash milestones under top five deals total ~$750 million in addition to royalties on any product sales
Diverse collaboration structures provide balanced risk/value structures
Multiple potential development milestones provide prospect of continual stream of value inflection events
Robust and growing pipeline of novel and proprietary drug candidates
Anticipated Near Term Milestones
Disco Target Med Preclinical IND Clinical Phases Products HTS very Valid Chem Early Mid
Oncology Drug Pipeline Oncology
A-B4 Anticipated 2H 06
Selection of Lead A B3 Hh Anticipated 1H 07
Undisclosed Pathway Screens
Hair Re- Selection of Lead Growth Anticipated 1H 07
BMP-7 BMP-7 Small Molecule Screens
Proprietary Drug Platform
Disco Target Med Preclinical IND Clinical Phases HTS very Valid Chem Early Mid Late
Multi-Target Oncology Drug Pipeline
Single agent targeting 2 or more validated targets (A+B):
Proprietary Compounds
- Based upon enhancements to functional groups of validated drugs and coupling the functional groups into single agents
Proprietary Drug Platform
Multi-Target Oncology Drug Pipeline
Curis is seeking to use this novel approach to provide combination
therapeutic synergies with reduced toxicity profiles of well validated targets / drugs as single agents
to use this novel approach therapeutic synergies with well validated targets / drugs as
Validated Targets and Validated Drug Prototypes
Starting with validated disease targets and known prototype drugs expected
3. Greatly speed development time
Source: CCL Research of Published Data
Multi-Target Inhibitors
The heterogeneity of cells within tumors as well as the redundancy of proliferative and survival
pathways favor the development of drugs that affect multiple pathways
Multi-targeted compounds that act synergistically are
expected to lead to superior efficacy with lower potential for dose limiting toxicities
The simultaneous inhibition of
several cellular targets by poly-pharmacological intervention might have even greater potential in preventing the emergence of drug resistance in human malignancies
Broxterman HJ et al. Drug Resist Updat. 8:183, 2005; Budillon A et al. Curr Drug Targets 6:241, 2005 Daub H et al. Nat Rev Drug Disc 3-1001 2004; Minucci S et al. Nat Rev Cancer. 6:38, 2006
Activity of Multi-Target Inhibitors in A431 Epithelial Carcinoma Cells
of Multi-Target Inhibitors on EGFR Inhibitor-Insensitive Cancer cells
Caspase 3/7 (fold change)
0.001 0.01 0.1 1 10 100
Concentrations (u M)
Synergy and Multi-Target Inhibitor Design
CDK MEK Inhibitor Inhibitor
Multikinase Inhibitor 1 EGFR
Multikinase Inhibitor 2
Inhibitor Others Inhibitor
Multi-Targeting Drug Platform:
A1- B1, B2 , B3 A2- B1, B2 , B3 A3- B1, B2 , B3 A4-
Dramatic need for enhanced med chem capacity to fully exploit the promise platform approach
US/EU cost prohibitive = China solution
More effective/efficient process for IP due diligence and filings
Curis has created a Chinese subsidiary
Operations to be located in Zhangjiang Hi-tech Park, Pudong, Shanghai Subsidiary to utilize CRO medicinal chemistry Cost of chemistry expected to approximate 25% of U.S. chemistry providers Expected to
allow for a greater number of drug programs
Overall scientific leadership, program management and in vitro and in vivo
animal work will continue to be conducted by Curis in the U.S.
Initially focused on development of small molecule drugs
that target validated cancer pathways
The formation of a Chinese subsidiary is expected to allow Curis to capitalize on the mature medicinal chemistry industry
that exists in China
Cost savings expected to allow Curis to increase number of drug programs and retain drug programs
beyond the mid-preclinical phase Wholly-owned subsidiary provides Curis with greater control over IP and process China subsidiary provides Curis with greater flexibility re: strategic alternatives Increase opportunities for Curis to advance drug
candidates into further preclinical and ultimately clinical studies Later-stage programs expected to enable Curis to pursue more advantageous development partnership terms in the future while maintaining control over the majority of the pipeline
Competencies and Enhanced Capacity & Productivity (Curis China)
Disco Target Med Preclinical IND Clinical Phases
Products HTS very Valid Chem Early Mid Late
Lead Drug Lead Back-up #1
Curis Curis Curis US China US
Competencies and Enhanced Capacity & Productivity (Curis China)
Disco Target Med Preclinical IND Clinical Phases
Products HTS very Valid Chem Early Mid Late
Lead Drug Lead Back-up #1
Curis Curis Curis US China US
Competencies and Enhanced Capacity & Productivity (Curis China)
Disco Target Med Preclinical IND Clinical Phases
Products HTS very Valid Chem Early Mid Late
Enhanced Capacity Lead Decreased Cost
Lead Increased Productivity Back-up #1 Decreased Time:
12 hr. time difference results in ~24 hr work schedule
Undisclosed Pathway Screens
Med Preclinical IND Clinical Phases HTS
Screens Hair Re-Growth
Small Molecule Cardio Screens
Target Med Preclinical IND Clinical Phases HTS
Valid Chem Early Mid Late
Screens Hair Re-Growth